Selected article for: "avian influenza and mortality rate"

Author: Skeik, Nedaa; Jabr, Fadi I.
Title: Influenza viruses and the evolution of avian influenza virus H5N1
  • Cord-id: xw7627x9
  • Document date: 2007_10_2
  • ID: xw7627x9
    Snippet: Although small in size and simple in structure, influenza viruses are sophisticated organisms with highly mutagenic genomes and wide antigenic diversity. They are species-specific organisms. Mutation and reassortment have resulted in newer viruses such as H5N1, with new resistance against anti-viral medications, and this might lead to the emergence of a fully transmissible strain, as occurred in the 1957 and 1968 pandemics. Influenza viruses are no longer just a cause of self-limited upper respi
    Document: Although small in size and simple in structure, influenza viruses are sophisticated organisms with highly mutagenic genomes and wide antigenic diversity. They are species-specific organisms. Mutation and reassortment have resulted in newer viruses such as H5N1, with new resistance against anti-viral medications, and this might lead to the emergence of a fully transmissible strain, as occurred in the 1957 and 1968 pandemics. Influenza viruses are no longer just a cause of self-limited upper respiratory tract infections; the H5N1 avian influenza virus can cause severe human infection with a mortality rate exceeding 50%. The case death rate of H5N1 avian influenza infection is 20 times higher than that of the 1918 infection (50% versus 2.5%), which killed 675 000 people in the USA and almost 40 million people worldwide. While the clock is still ticking towards what seems to be inevitable pandemic influenza, on April 17, 2007 the U.S. Food and Drug Administration (FDA) approved the first vaccine against the avian influenza virus H5N1 for humans at high risk. However, more research is needed to develop a more effective and affordable vaccine that can be given at lower doses.

    Search related documents:
    Co phrase search for related documents
    • absence presence and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • absence presence and long distance: 1
    • absence presence and long duration: 1, 2
    • absence presence and long interval: 1, 2
    • absence presence and low pathogenic: 1
    • acute ards respiratory distress syndrome and lobar consolidation: 1, 2, 3
    • acute ards respiratory distress syndrome and lobar consolidation segmental: 1, 2
    • acute ards respiratory distress syndrome and long duration: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and low appear: 1
    • acute ards respiratory distress syndrome and low dose effective: 1
    • acute ards respiratory distress syndrome and low pathogenic: 1
    • acute respiratory syndrome and additional step: 1, 2, 3
    • acute respiratory syndrome and lobar consolidation: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory syndrome and lobar consolidation segmental: 1, 2
    • acute respiratory syndrome and long distance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • acute respiratory syndrome and long duration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and long interval: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory syndrome and low appear: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory syndrome and low dose effective: 1, 2, 3, 4, 5, 6, 7